BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26346300)

  • 1. A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.
    Shafuddin E; Mills GD; Holmes MD; Poole PJ; Mullins PR; Black PN
    J Negat Results Biomed; 2015 Sep; 14():15. PubMed ID: 26346300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
    van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
    Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
    Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
    Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
    Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.
    Allinson JP; Vlies BH; Brill SE; Law M; Burnside G; Finney LJ; Alves-Moreira L; Donaldson GC; Calverley PMA; Walker PP; Wedzicha JA
    Am J Respir Crit Care Med; 2023 Sep; 208(5):549-558. PubMed ID: 37450935
    [No Abstract]   [Full Text] [Related]  

  • 14. Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.
    Finch AP; van Velzen P; Ter Riet G; Sterk PJ; Prins JM; Bosmans JE
    Pharmacoeconomics; 2019 May; 37(5):689-699. PubMed ID: 30565022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
    Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
    Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
    Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD.
    Matthys H; Pliskevich DA; Bondarchuk OM; Malek FA; Tribanek M; Kieser M
    Respir Med; 2013 May; 107(5):691-701. PubMed ID: 23478193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Theophylline in the treatment of chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study].
    Zhou YM; Wang XP; Zeng XY; Qiu R; Xie JF; Liu SM; Zheng JP; Zhong NS; Ran PX
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):577-82. PubMed ID: 17129461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
    Daniels JM; Snijders D; de Graaff CS; Vlaspolder F; Jansen HM; Boersma WG
    Am J Respir Crit Care Med; 2010 Jan; 181(2):150-7. PubMed ID: 19875685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.